Evidence map›Paper›PMID 26724694›Full record

Trial reportJournal of affective disorders2016

Predictors of depression recovery in HIV-infected individuals managed through measurement-based care in infectious disease clinics.

Nathaniel A Sowa, Angela Bengtson, Bradley N Gaynes, Brian W Pence

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of affective disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nathaniel A SowaDepartment of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA. Electronic address: nathaniel_sowa@med.unc.edu.
Angela BengtsonDepartment of Epidemiology, University of North Carolina School of Public Health, Chapel Hill, NC, USA.
Bradley N GaynesDepartment of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Brian W PenceDepartment of Epidemiology, University of North Carolina School of Public Health, Chapel Hill, NC, USA.
University of North Carolina at Chapel Hill · US

Funding

Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
UNC CLINICAL AND TRANSLATIONAL SCIENCE AWARD: BPCAUL1RR025747 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RUNGE, MARSCHALL S. · 2008 to 2011
$44.6M
North Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9M
UNC Clinical Translation Science Award-K12 Scholars Program (KL2)KL2RR025746 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RUNGE, MARSCHALL S. · 2008 to 2011
$9.0M
North Carolina Translational & Clinical Sciences Institute (NC TraCS)KL2TR001109 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$5.7M
Improving HAART Adherence in Depressed HIV Clinic Patients: A Real-World RCTR01MH086362 · NIMH · DUKE UNIVERSITY · PI PENCE, BRIAN W · 2009 to 2013
$3.5M
NCATS NIH HHS KL2 TR001109NCATS NIH HHS UL1 TR001111NCATS NIH HHS UL1 TR002489NCRR NIH HHS KL2 RR025746NCRR NIH HHS KL2RR025746NCRR NIH HHS UL1 RR025747NCRR NIH HHS UL1RR025747NIAID NIH HHS P30 AI027767NIAID NIH HHS P30-AI027767NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI064518NIAID NIH HHS P30-AI064518NIAID NIH HHS P30-AI50410NIMH NIH HHS R01 MH086362NIMH NIH HHS R01MH086362PHS HHS TLRR025745
6 · The paper itself

Abstract

backgroundTreatment of comorbid chronic disease, such as depression, in people living with HIV/AIDS (PLWHA) increasingly falls to HIV treatment providers. Guidance in who will best respond to depression treatment and which patient-centered symptoms are best to target is limited.

methodsBivariable analyses were used to calculate hazard ratios for associations between baseline demographic, mental health-related, and HIV-related factors on time to first depression remission among PLWHA enrolled in a randomized trial of measurement-based antidepressant management. Time-updated factors also were analyzed at time of antidepressant (AD) initiation/adjustment and 8 weeks post AD initiation/adjustment.

resultsBaseline comorbid depression and anxiety; comorbid depression, anxiety and substance abuse; and generalized anxiety disorder predicted a slower time to first remission. Being on ART but non-adherent, having panic disorder, having a history of a major depressive episode, or having been in HIV care for >10 years prior to study initiation predicted a faster time to first remission. Sleep difficulty or fatigue at the time of AD initiation/adjustment predicted a slower time to remission. In non-remitters at 8 weeks post AD initiation/adjustment, sleep difficulty, anxiety, and fatigue each predicted a slower time to remission. LIMITATIONS: Remission was determined by PHQ-9 scores, not diagnostic criteria. The results may apply only to depression recovery in this particular model of treatment. We conducted only exploratory analyses to determine magnitude of effects.

conclusionsBaseline comorbid anxiety with or without substance abuse predicts slower time to depression remission among PLWHA treated in HIV clinics. Targeting anxiety or fatigue at the time of AD initiation/adjustment or sleep difficulty, anxiety, and fatigue at 8 weeks post AD initiation/adjustment could shorten time to depression remission in this model.

Indexed as

AdultAgedAntidepressive AgentsAntiviral AgentsAnxietyAnxiety DisordersComorbidityDepressionFatigueFemaleHIV InfectionsHumansMajor Depressive DisorderMaleMiddle AgedPatient ComplianceAntidepressive AgentsAntiviral AgentsDepressionDepression treatmentHIVMeasurement-based careRemission predictors

Identifiers

PMID26724694
PMCPMC4728048
OpenAlexW2204684122

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.